• Home
  • About Us
    • Company Overview
    • Management
    • Board of Directors
    • Advisors
    • Partnerships
    • Careers
  • Research & Development
    • Pipeline
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Quote & Chart
    • Analyst Coverage
    • SEC Filings
    • Quarterly Results
    • Governance
    • FAQs
  • Contact

Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Nov 13, 2026 | Press Releases

– FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVER-2 trial and a future NDA submission – – U.S. patent office has granted priority examination (Track 1) for the composition of matter patent...

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

Sep 22, 2026 | Press Releases

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/ CUPERTINO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE)...

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 12, 2026 | Press Releases

– U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 – – FDA feedback on use of new brilaroxazine formulation in the...

Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

Jun 23, 2026 | Press Releases

– The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at VirtualInvestorConferences.com -CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE)...

Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase

May 18, 2026 | Press Releases

CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to...
« Older Entries

Recent Posts

  • Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
  • Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
  • Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
  • Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
  • Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase

Recent Comments

No comments to show.

CONTACT

Reviva Pharmaceuticals Holdings, Inc.
10080 N Wolfe Road, Suite SW3-200
Cupertino, CA 95014

Phone: +1.408.501.8881
Email: [email protected]

  • Follow
  • Follow
  • Follow
Sign Up for Email Alerts

SITE LINKS

  • Home
  • Investors
  • Newsroom
  • Privacy Policy
  • Contact
  • Sitemap

Our COMPANY

  • About us
  • Management
  • Board of Directors
  • Advisors
  • Partnerships
  • Careers

RESEARCH & DEVELOPMENT

  • Pipeline
  • Clinical Trials
  • Publications
Reviva Pharmaceuticals Holdings, Inc. ©2026.   All Rights Reserved.
We value your privacy. We use cookies and other technologies to keep the site reliable and secure, measure site performance, tailor your experience, and deliver up to date stock data and financial information. By using our site, you agree to our use of cookies as described in our Privacy Policy.